Skip to content

Disc Medicine IRON Change in AP

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$35.6M+35.9%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$3M+143%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$4.99M-77.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$2.22M-41.6%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$11.81M-42.2%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's change in AP?
Disc Medicine (IRON) reported change in AP of $2.74M in Q1 2026.
How has Disc Medicine's change in AP changed year-over-year?
Disc Medicine's change in AP increased by 314.6% year-over-year, from -$1.28M to $2.74M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.